In morning trade the Botanix Pharmaceuticals Ltd (ASX: BOT) share price has been one of the best performers on the local market with a huge move higher.
At the time of writing the dermatology company’s shares are up 61% to 21 cents.
This morning Botanix advised that it has successfully completed a Phase 1b study in patients with moderate to severe acne.
According to the release, the study met all designated endpoints and large reductions in acne lesions were observed after four weeks of treatment. Pleasingly, the treatment was significantly better than the current leading topical acne products.
In addition to this, the topical application of BTX 1503 was safe and very well-tolerated, with no reported signs of skin irritation.
As a result, the company plans to rapidly advance BTX 1503 into a Phase 2 acne patient study in North America and Australia in the second-quarter of calendar year 2018.
What is BTX 1503?
BTX 1503 is a topically applied synthetic cannabidiol acne product that offers localised delivery areas on the skin with the disease. For this reason Botanix is often categorized as a medicinal cannabis company alongside the likes of Auscann Group Holdings Ltd (ASX: AC8), Hydroponics Company Ltd (ASX: THC), and MGC Pharmaceuticals Ltd (ASX: MXC).
Should you invest?
As I have said previously, I feel Botanix could have an extremely bright future thanks to its BTX 1503 product and Permetrex proprietary drug delivery system.
After all, the acne prescription market is expected to be worth up to US$4.5 billion per year by 2018 and current oral treatments have horrific side effects.
However, a phase 2 trial will not be cheap and the company may need to raise funds for it in my opinion. But considering this positive news, I don’t think it will be short of support from institutional investors.
If there's one thing for sure, 2020 has been the year we embraced sanitisation. Scott Phillips has discovered a little-known Australian healthcare company could be set to reap the rewards of the post-covid world.
Better yet, this fast-growing company is currently trading at a 30% discount from its highs. Scott believes in this stock so much, he's staked $209k of our own company money on it. Forget 'buy now pay later', this stock could be the next hot stock on the ASX.
Scott and his team have published a detailed report on this tiny ASX stock. Find out how you can access our TOP healthcare stock today!
As of 2.11.2020
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
- Why Ampol, Flight Centre, Syrah, & Telix shares are dropping lower – January 25, 2021 12:47pm
- ASX 200 up 0.35%: Afterpay & Appen push higher, big four banks rising – January 25, 2021 12:02pm
- Why IDP Education, Lake Resources, Mach7, & Tyro shares are shooting higher – January 25, 2021 11:40am